RNA-seq analysis of mouse NSCLC tissues in the PBS, Taraxasterol (Tara), DC tumor vaccine and Taraxasterol combined with DC tumor vaccine group
Purpose:gene discrepancy analysis and signaling pathway of tumor tissues in the PBS, Taraxasterol, DC tumor vaccine and Taraxasterol combined with DC tumor vaccine group Overall design: Methods: C57BL/6 wild-type (6-8 weeks old) was used to prepare a mouse NSCLC model use LLC cells injected into the dorsal side of the mouse. 7 days after tumor cell inoculation with confirmation of successful maturation of tumors, mice were randomly divided into 4 groups: PBS control group; Tara group (Tara); DCs-vac group (DCs); Tara combined with DCs-vac group (D+T). PBS group: intraperitoneal injection of PBS, 0.2ml per mouse, once every 3 days, a total of 6 injections. Tara group: intraperitoneal injection of tara, 10mg/kg, once every 3 days, a total of 6 injections. DCs group: tail vein injection of DCs-vac,inject once every 7 days, with a total of 3 interventions. D+T group:12 hours after the first intraperitoneal injection of Tara (10mg/kg) , DCs-vac was injected into the tail vein. Tara is injected every 3 days, with a total of 6 interventions. DCs-vac is injected once every 7 days, with a total of 3 interventions. A total amount of 1-3µg RNA per sample was used as input material for the RNA sample preparations. The purity of the sample was determined by NanoPhotometer ®(IMPLEN, CA, USA;The concentration and integrity of RNA samples were detected by Agilent 2100 RNA nano 6000 assay kit (Agilent Technologies, CA, USA).